🇺🇸 FDA
Pipeline program

GLPG0634

GLPG0634-CL-201

Phase 2 small_molecule completed

Quick answer

GLPG0634 for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 4 ClinicalTrials.gov record(s).

Program details

Company
Lakefront Biotherapeutics NV
Indication
Rheumatoid Arthritis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials